Výsledky vyhledávání - "David C. Van Echo"

Treatment of Leptomeningeal Carcinomatosis in a Patient with Metastatic Pancreatic Cancer: A Case Report and Review of the Literature

Autor: Mary Kwok, David C. Van Echo, Patrick E. Young, William Rainey Johnson, Brett Theeler

Publikováno v: Case Reports in Oncology, Vol 11, Iss 2, Pp 281-288 (2018)
Case Reports in Oncology

Pancreatic cancer is the fourth leading cause of cancer-related death with a median survival of 3–11 months when metastatic. We present a patient with metastatic pancreatic cancer and an exceptional response to initial systemic chemotherapy with FO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76738d443f4e94367f9c6056aea4e15
https://www.karger.com/Article/FullText/489085

Zobrazit plný text záznamu

Gallbladder Carcinoma, the Difficulty of Early Detection: A Case Report

Autor: Andrew E Graff, Hugh M Dainer, David C. Van Echo, Stephen L. Lewis, Jonathan R Bear

Publikováno v: Cureus

Gallbladder carcinoma (GBC) is an uncommon malignancy with a high mortality rate. Detecting gallbladder carcinoma in its early stages can be difficult, despite improvements in ultrasound and computed tomography (CT) imaging. Most diagnoses of GBC are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9a93d3274c591caae1e6f71e31e48c3
http://europepmc.org/articles/PMC4792642

Zobrazit plný text záznamu

AE37: a novel T-cell-eliciting vaccine for breast cancer

Autor: George E. Peoples, Constantin N. Baxevanis, Jarrod P. Holmes, Guy T. Clifton, Nathan M. Shumway, Alan K. Sears, M. G. Carmichael, Michael Papamichail, Sathibalan Ponniah, Linda C. Benavides, Jeremy D. Gates, Kevin S. Clive, Sonia A. Perez, Elizabeth A. Mittendorf, David C. Van Echo

Publikováno v: Expert Opinion on Biological Therapy. 11:1543-1550

Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8+ T-cell-el

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::566ce1e29c923a240637835e8b30a9f3
https://doi.org/10.1517/14712598.2011.616889

Zobrazit plný text záznamu

Biomarker correlation to clinical response in phase I/II trials of the adjuvant breast cancer vaccine neuvax (nelipepimut-S or E75)

Autor: Jarrod P. Holmes, Timothy J. Vreeland, Sathibalan Ponniah, Alfred F. Trappey, Alan K. Sears, John S. Berry, George E. Peoples, David C. Van Echo, Diane F. Hale, Guy T. Clifton, Ritesh Patil, Elizabeth A. Mittendorf

Publikováno v: Journal of Clinical Oncology. 31:TPS3126-TPS3126

TPS3126 Background: We completed phase I/II clinical trials with NeuVax (nelipepimut-S), a HLA-A2/A3-restricted, HER2-derived peptide vaccine. The vaccine was administered in the adjuvant setting to prevent recurrence in breast cancer patients render

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::149952f43ad9930c20ae8a29c5f82e1c
https://doi.org/10.1200/jco.2013.31.15_suppl.tps3126

Zobrazit plný text záznamu

Abstract LB-413: Circulating regulatory T cells (CD4+CD25high CD127low) decrease in breast cancer patients after vaccination with a modified HER-2/neu HLA class II peptide (AE37) vaccine

Autor: George E. Peoples, Mohamed Mursal, Athina Zacharia, Sathibalan Ponniah, Yusuf Jama, Anna Chiplis, David C. Van Echo, Elizabeth A. Mittendorf, Alan K. Sears, Guy T. Clifton, Jarrod P. Holmes

Publikováno v: Cancer Research. 71:LB-413

BACKGROUND: Regulatory T cells (TReg) are elevated in breast cancer patients with the number of TReg cells being inversely associated with clinical outcome. We are conducting a prospective, randomized phase II trial of the HER-2/neu peptide vaccines

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1afab2e47cc42c86438dea7eabdadcfd
https://doi.org/10.1158/1538-7445.am2011-lb-413

Zobrazit plný text záznamu

Abstract LB-414: Comparison of in vitro and in vivo immunologic responses in a prospective, randomized, single-blinded phase II trial evaluating the HER-2/neu peptide vaccines GP2 and AE37 in breast cancer patients

Autor: Sathibalan Ponniah, Yusuf Jama, Mark G. Carmichael, Elizabeth A. Mittendorf, Anna Chiplis, Alan K. Sears, Mohamed Mursal, Athina Zacharia, Guy T. Clifton, David C. Van Echo, Jarrod P. Holmes, George E. Peoples

Publikováno v: Cancer Research. 71:LB-414

BACKGROUND: We are conducting a prospective, randomized, single-blinded phase II trial evaluating the HER-2/neu peptide vaccines AE37 and GP2 in the adjuvant setting to prevent breast cancer recurrence. AE37 is the Ii-Key hybrid of the HER-2/neu pept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc4998477aaecd66163ce28f93ce0a42
https://doi.org/10.1158/1538-7445.am2011-lb-414

Zobrazit plný text záznamu

Response to High Dose (HD) Imatinib Therapy in Relapsed c-kit+ Acute Myeloid Leukemia (AML)

Autor: David C. Van Echo, Gauri V. Alvarez, Edwarda M. Buda, Brendan M. Weiss, Daniel L. Cruser, Thomas J. Reid

Publikováno v: Blood. 104:4532-4532

BACKGROUND. c-kit is a receptor tyrosine kinase for the ligand stem cell factor and a member of the PDGF receptor family. c-kit positivity, as defined by the presence of CD117 by flow cytometry (FC) in > 20% blasts, is detected in up to 90% of patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3118d92a5fdf7d0d12efa7cbb4d4f874
https://doi.org/10.1182/blood.v104.11.4532.4532

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání